Medical News


Recurrent low-grade carcinoma of the ovary less responsive to chemo

Recurrent low-grade serous carcinoma, a rare type of ovary cancer, is less sensitive to chemotherapy and therefore more difficult to treat than more common high-grade ovary cancers, as per scientists from The University of Texas M. D. Anderson Cancer Center. The findings were reported at the Society of Gynecologic Oncologists 39th Annual Meeting on Women’s Cancers……..

Original post by Health news from medicineworld.org

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists



Related Articles
  • Drug Boosts Survival in Recurrent Ovarian Cancer
  • Chemo plus tamoxifen a go, ovary suppression a no
  • Advanced-stage ovarian cancer patients with BRCA live longe
  • Women without regular medical care
  • Low-Fat Dietary To Lower Risk of Ovarian Cancer
  • No comments yet. Be the first.

    Leave a reply

    Recurrent low-grade carcinoma of the ovary less responsive to chemo

    Recurrent low-grade serous carcinoma, a rare type of ovary cancer, is less sensitive to chemotherapy and therefore more difficult to treat than more common high-grade ovary cancers, as per scientists from The University of Texas M. D. Anderson Cancer Center. The findings were reported at the Society of Gynecologic Oncologists 39th Annual Meeting on Women’s Cancers……..

    Original post by Health news from medicineworld.org

    Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
    • Digg
    • del.icio.us
    • Netvouz
    • DZone
    • ThisNext
    • MisterWong
    • Wists



    Related Articles
  • Drug Boosts Survival in Recurrent Ovarian Cancer
  • Chemo plus tamoxifen a go, ovary suppression a no
  • Advanced-stage ovarian cancer patients with BRCA live longe
  • Women without regular medical care
  • Low-Fat Dietary To Lower Risk of Ovarian Cancer
  • No comments yet. Be the first.

    Leave a reply